Drugs for rare diseases: influence of orphan designation status on price

SID > Fuentes Documentales > Publicaciones Periódicas > Artículos de Revistas > Drugs for rare diseases: influence of orphan designation status on price

Resumen

The literature indicates that the expenditure on orphan drugs will be increasing over the coming years. The market for orphan drugs has inherent market characteristics that sometimes result in high prices. The aim of this study was to analyse whether awarding orphan designation status has an influence on the price setting of drugs for rare disease indications. To this effect, prices of designated orphan drugs were compared with other non-designated drugs for rare disease indications. We identified 28 designated orphan drugs and 16 comparable non-designated drugs for rare disease indications for which we collected official hospital prices (per defined daily dose) in Belgium in 2010. Orphan-designated drugs had a higher median price (138.56 Euros [interquartile range; IQR 406.57 Euros]) than non-designated drugs (16.55 Euros [IQR 28.05 Euros]) for rare disease indications (p < 0.01). In conclusion, our results suggest that awarding orphan designation status in itself is associated with higher prices for drugs for rare disease indications. In order to gain full insight into orphan drug pricing mechanisms, future research should focus on collecting information about the different factors influencing orphan drug pricing.

Resumen realizado por los autores recogido de la publicación

Publicación

Nueva Zelanda:
Applied Health Economics And Health Policy,
2011

ISBN

Descripción física

275-279

Serie

Quizás te interese:

Recibe más documentos en tu email

No te pierdas todas nuestras actualizaciones